Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals and Torii Pharmaceutical Expand Collaboration to Combat Common Warts in Global Phase 3 Trial

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced this week an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. This collaboration marks a critical step …

Verrica Pharmaceuticals and Torii Pharmaceutical Expand Collaboration to Combat Common Warts in Global Phase 3 Trial Read More
InterDigital

InterDigital Inks Patent License Agreement with Samsung, Bolstering its Position in Consumer Electronics

WILMINGTON, DE — InterDigital, Inc. (Nasdaq: IDCC), a heavyweight in the mobile and video technology industry, has announced a new patent licensing agreement with global electronics giant Samsung. This strategic …

InterDigital Inks Patent License Agreement with Samsung, Bolstering its Position in Consumer Electronics Read More

Venatorx Pharmaceuticals

Venatorx Pharmaceuticals Strikes Deal with Menarini Group for Global Rights to Cefepime-Taniborbactam

MALVERN, PA — Venatorx Pharmaceuticals recently granted exclusive commercial rights to Italy’s Menarini Group for its novel antibiotic, cefepime-taniborbactam. The agreement extends to 96 countries in Europe, Latin America, Middle …

Venatorx Pharmaceuticals Strikes Deal with Menarini Group for Global Rights to Cefepime-Taniborbactam Read More
InterDigital

InterDigital and Panasonic Renew Patent Licenses: A Strategic Move in the Entertainment and Communication Space

WILMINGTON, DE — InterDigital, Inc. (Nasdaq: IDCC) has announced the renewal of its patent license agreements with Panasonic Entertainment & Communication Co., Ltd. This move not only extends Panasonic’s license …

InterDigital and Panasonic Renew Patent Licenses: A Strategic Move in the Entertainment and Communication Space Read More
Federal Trade Commission

FTC Dismisses Case Against Sanofi After Termination of Proposed Acquisition of Pompe Disease Drug License from Maze Therapeutics

The Federal Trade Commission (FTC) recently announced that it has moved to dismiss its case against pharmaceutical giant Sanofi following the company’s decision to terminate its proposed acquisition of an …

FTC Dismisses Case Against Sanofi After Termination of Proposed Acquisition of Pompe Disease Drug License from Maze Therapeutics Read More